MAP2 immunolabeling percentage: Equal numbers of gliomas were scored 3 (30/78; 38.5%) and 2 (30/78; 38.5%), while fewer scored 1 (18/78; 23%). The gene discussed is MAP2; the disease is central nervous system cancer.